海王生物：预计2025年年度净利润亏损4.9亿元~6亿元

Core Viewpoint - The company, Haiwang Biological, anticipates a net loss attributable to shareholders of approximately 490 million to 600 million yuan for 2025, with basic earnings per share projected to be a loss of 0.1862 to 0.228 yuan. This is an improvement compared to the previous year's loss of about 1.193 billion yuan, or a loss of 0.4536 yuan per share. The primary reason for this performance change is the optimization of business structure, which has impacted short-term results [1]. Financial Performance - The expected net loss for 2025 is between 490 million and 600 million yuan, with basic earnings per share losses ranging from 0.1862 to 0.228 yuan [1]. - In the previous year, the company reported a net loss of approximately 1.193 billion yuan, with basic earnings per share losses of 0.4536 yuan [1]. Strategic Initiatives - The company aims to enhance sales gross margin, ensure asset safety, improve financing channels, and optimize capital returns as part of its management philosophy for 2025 [1]. - The focus will be on cash flow as the core element, with the goal of maximizing efficiency in all operational activities [1]. - The company is conducting a comprehensive evaluation of long-term loss-making subsidiaries or business segments that do not align with its core strategy, planning to divest poor assets through methods such as equity transfer, asset sales, and liquidation [1]. Operational Adjustments - Some subsidiaries have had their operations halted, which is expected to impact the net profit loss for the reporting period by approximately 110 million to 150 million yuan due to ongoing liquidation processes [1]. - Although these measures will affect the company's overall operational scale and profit contributions in the short term, they are intended to effectively optimize asset quality and cash flow, laying a solid foundation for the company's long-term healthy and steady development [1].